
Ascendis Pharma has released the final phase III data from its clinical studies of candidate Transcon PTH as a treatment for hypoparathyroidism, which causes cramps and muscle spasms due to low levels of calcium and PTH.
In a press release, the firm writes that Transcon PTH showed statistical significance compared to the control group. 78.5 percent of the patients given Transcon PTH showed improvement, compared to 4.8 percent of patients in the control group.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app